See more : eXmotion Co., Ltd. (4394.T) Income Statement Analysis – Financial Results
Complete financial analysis of Genenta Science S.p.A. (GNTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genenta Science S.p.A., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Network Media Group Inc. (NETWF) Income Statement Analysis – Financial Results
- Mastek Limited (MASTEK.BO) Income Statement Analysis – Financial Results
- Greenyn Biotechnology Co., Ltd (6846.TWO) Income Statement Analysis – Financial Results
- Vital Limited (VTL.NZ) Income Statement Analysis – Financial Results
- Korporacja Gospodarcza efekt S.A. (EFK.WA) Income Statement Analysis – Financial Results
Genenta Science S.p.A. (GNTA)
About Genenta Science S.p.A.
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 41.58K | 6.03K | 5.08K | 1.77K | 0.00 |
| Gross Profit | -41.58K | -6.03K | -5.08K | -1.77K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.47M | 5.34M | 3.39M | 4.69M | 3.70M |
| General & Administrative | 5.26M | 5.71M | 2.30M | 901.77K | 921.52K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.26M | 5.71M | 2.30M | 901.77K | 921.52K |
| Other Expenses | 0.00 | 242.55K | -150.00K | 5.97K | 36.33K |
| Operating Expenses | 11.73M | 11.04M | 5.54M | 5.59M | 4.62M |
| Cost & Expenses | 11.73M | 11.04M | 5.54M | 5.59M | 4.62M |
| Interest Income | 0.00 | 36.99 | 11.72 | 7.75 | 9.55 |
| Interest Expense | 0.00 | 0.00 | 11.72K | 7.75K | 9.55K |
| Depreciation & Amortization | 42.45K | 6.03K | 5.08K | 1.77K | 4.62M |
| EBITDA | -11.69M | -11.04M | -5.68M | -5.59M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -11.73M | -11.04M | -5.69M | -5.59M | -4.62M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 87.49K | 2.57M | 157.94K | -1.79K | 26.78K |
| Income Before Tax | -11.65M | -8.48M | -5.53M | -5.59M | -4.60M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.85M | 31.37K | 13.72K | 9.55K |
| Net Income | -11.65M | -3.62M | -5.56M | -5.61M | -4.61M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.64 | -0.20 | -0.31 | -0.31 | -0.25 |
| EPS Diluted | -0.64 | -0.20 | -0.31 | -0.31 | -0.25 |
| Weighted Avg Shares Out | 18.22M | 18.22M | 18.22M | 18.12M | 18.12M |
| Weighted Avg Shares Out (Dil) | 18.22M | 18.22M | 18.22M | 18.12M | 18.12M |
Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”
Genenta's CEO to present at the U.S. Senate, Washington D.C.at the meeting “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatl
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer
MILAN and NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that the Agenzia Italiana del Farmaco (AIFA) has approved a new Phase...
7 Penny Biotech Stocks to Triple Your Investment
One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny biotech stocks.
Genenta Welcomes New Directors John L. Cantello, Lauren H.
MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it...
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial
Genenta to Present at Upcoming Scientific and Investor Conferences
MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells towards a permanent self-vaccination against cancer, will present at...
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments
Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication
Genenta to Present at Upcoming Scientific and Investor Conferences
MILAN, Italy and NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, will present at several...
Genenta to Present at Upcoming Investor Conferences
MILAN, Italy and NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, will present at several...
Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA
MILAN, Italy and NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, will be presenting at several upcoming scientific congresses in...
Source: https://incomestatements.info
Category: Stock Reports